Physician profile
Millicent E Kee
NPI 1972767804
$1,453.59
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $240 · 2023: $410 · 2024: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $237.38 | 2021-2024 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $171.02 | 2021-2022 | |
| Astellas Pharma US INC | $129.88 | 2021-2022 | |
| Medtronic, INC. | $113.12 | 2023-2024 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $110.25 | 2023-2024 | Mounjaro, Baqsimi, Lyumjev |
| Merck Sharp & Dohme LLC | $82.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.87 | 2023-2024 | Synjardy, Jardiance |
| Novo Nordisk INC | $47.53 | 2023-2024 | Ozempic, Rybelsus |
| Insulet Corporation | $34.55 | 2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $33.22 | 2023-2024 | Gvoke Hypopen |
| Dexcom, INC. | $33.02 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $29.03 | 2023 | |
| Esperion Therapeutics, INC. | $26.22 | 2021 | |
| Tandem Diabetes Care, INC. | $18.66 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.30 | 2021 | |
| Amgen INC. | $17.58 | 2021 | |
| Radius Health, INC. | $17.53 | 2024 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $14.33 | 2023 | Farxiga |
| Pfizer INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Kee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.